ARHGAP39 and thyroid gland carcinoma: ARHGAP39 was significantly decreased in 7 cancers: glioblastoma multiforme (GBM), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), thyroid carcinoma (THCA), testicular germ cell tumors (TGCT), adrenocortical carcinoma (ACC), and kidney chromophobe (KICH).